

AMENDMENTS TO THE CLAIMS

LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 4. (Canceled)
5. (Currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence ~~selected from the group consisting of:~~
 - ~~(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12;~~
 - ~~(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;~~
 - ~~(c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12;~~
 - ~~(d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, and 12, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;~~
 - ~~(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and~~
 - ~~(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).~~
6. (Currently amended) An isolated ~~The~~ nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the a nucleotide sequence that is the complement of the nucleic acid sequence of claim 5. ~~SEQ ID NO: of a naturally occurring allelic nucleic acid variant.~~
7. – 8. (Canceled)
9. (Currently amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence ~~selected from the group consisting of:~~
 - ~~(a) a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, and 11;~~

- (b) ~~a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, and 11, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;~~
- (c) ~~a nucleic acid fragment of (a); and~~
- (d) ~~a nucleic acid fragment of (b).~~
10. – 11. (Canceled)
12. (Currently amended) A vector comprising the nucleic acid molecule of claim ~~4~~ 5.
13. (Original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. (Currently amended) An isolated cell comprising the vector of claim 12.
15. - 18. (Canceled)
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
- (a) providing the sample;
 - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
 - (c) determining the presence or amount of the probe bound to said nucleic acid molecule,
- thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
21. The method of claim 20 wherein the cell or tissue type is cancerous.
22. – 38. (Canceled)
39. (Currently amended) A ~~pharmaceutical~~ composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
40. – 41. (Canceled)
42. (Currently amended) A kit comprising in one or more containers, the ~~pharmaceutical~~ composition of claim 39.